Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan long-term extension in pediatric pulmonary arterial hypertension
NL-OMON34600Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ambrisentan in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH), sponsored by GSK. Primary endpoint: Adverse events. Planned start Nov 2010; status: withdrawn.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NL-OMON34600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34600.